文献速递头颈部肿瘤放疗

局部晚期鼻咽癌同期-辅助放化疗:探索实现最佳10年治疗比

Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma-Exploration for Achieving Optimal 10-Year Therapeutic Ratio.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-05-02

该研究汇总2项随机试验(NPC-9901和NPC-9902)的10年结局,比较单纯放疗(218例)与同期-辅助放化疗(223例)在III-IVB期非角化性鼻咽癌中的疗效。放化疗组10年无失败生存率、无进展生存率和总生存率均显著提高,且未显著增加晚期毒性或非癌死亡。探索性分析提示同期顺铂周期数可由3周期减至2周期而不影响生存获益,但需进一步验证。

要点

  • 放化疗组10年无失败生存率62% vs 52%(P=0.016),无进展生存率56% vs 44%(P=0.008),总生存率60% vs 50%(P=0.044)。
  • 放化疗组总体晚期毒性发生率51% vs 48%(P=0.34),非癌死亡19% vs 16%(P=0.52),均无显著增加。
  • 接受3周期同期顺铂者听力损伤发生率40% vs 接受2周期者24%(P=0.017),同期周期数可考虑由3减至2。

核心结论

  • 在放疗基础上加用同期顺铂及辅助顺铂-氟尿嘧啶可显著改善总生存和疾病控制,且未显著增加晚期毒性或非癌死亡。
  • 探索性分析提示同期和辅助阶段均对肿瘤控制有贡献;同期顺铂周期数可由3周期减至2周期以获得相似生存获益而不致过度增加听力损伤,此假说需进一步验证。

研究设计与样本

  • 更新汇总2项随机研究(NPC-9901和NPC-9902试验)的联合分析。
  • 纳入III-IVB期非角化性鼻咽癌患者,随机分配至单纯放疗组(218例)或放化疗组(223例)。
  • 放化疗组方案:3周期顺铂(100 mg/m2)同期放疗,随后3周期顺铂(80 mg/m2)和氟尿嘧啶(1000 mg/m2/天,连用4天)。
  • 所有患者接受常规分割放疗至≥66 Gy,中位随访13.9年。

主要发现

  • 意向性分析显示放化疗组10年无失败生存率显著优于放疗组(62% vs 52%,P=0.016)。
  • 放化疗组10年无进展生存率显著优于放疗组(56% vs 44%,P=0.008)。
  • 放化疗组10年总生存率显著优于放疗组(60% vs 50%,P=0.044)。
  • 放化疗组与放疗组总体晚期毒性发生率无显著差异(51% vs 48%,P=0.34),非癌死亡亦无显著差异(19% vs 16%,P=0.52)。
  • 探索性分析显示同期顺铂2周期与3周期的疾病控制无差异,但3周期组听力损伤显著增加(40% vs 24%,P=0.017);仅接受≥2周期辅助顺铂-氟尿嘧啶者远处控制显著改善(73% vs 65%,P=0.037)且生存获益最大。

关键数值与推荐

  • 同期顺铂剂量为100 mg/m2,辅助顺铂为80 mg/m2,氟尿嘧啶为1000 mg/m2/天连用4天。
  • 放疗为常规分割,剂量≥66 Gy。
  • 探索性分析提示同期顺铂周期数可由3周期减至2周期以获相似生存获益而不致过度增加听力损伤。

临床怎么用

  • 对于III-IVB期非角化性鼻咽癌,可考虑在放疗基础上加用同期顺铂及辅助顺铂-氟尿嘧啶以改善10年生存和疾病控制。
  • 探索性分析提示同期顺铂2周期与3周期疾病控制无差异,3周期者听力损伤增加,同期周期数可考虑由3减至2。
  • 仅接受≥2周期辅助顺铂-氟尿嘧啶者远处控制显著改善且生存获益最大。

局限性

  • 同期周期数由3减至2的假说需进一步验证(原文:This is a useful hypothesis that warrants further validation)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This is an updated combined analysis of 2 randomized studies (NPC-9901 and NPC-9902 trials) to evaluate the 10-year outcome attributed to the addition of concurrent-adjuvant chemotherapy for advanced locoregional nasopharyngeal carcinoma (NPC). PATIENTS AND METHODS: Eligible patients with stage III-IVB nonkeratinizing NPC were randomly assigned to radiation therapy alone (RT: 218 patients) or chemoradiation therapy (CRT: 223 patients) using 3 cycles of cisplatin (100 mg/m2) concurrent with RT, followed by 3 cycles of cisplatin (80 mg/m2) and fluorouracil (1000 mg/m2/day for 4 days). All of the patients were irradiated with conventional fractionation to ≥66 Gy. The median follow-up was 13.9 years. RESULTS: Intention-to-treat analysis confirmed that the CRT group achieved significant improvement in 10-year failure-free rate (FFR: 62% vs 52%, P = .016), progression-free survival rate (PFS: 56% vs 44%, P = .008), and overall survival rate (OS: 60% vs 50%, P = .044). There was no significant increase in overall late toxicity rate (51% vs 48%, P = .34) or noncancer deaths (19% vs 16%, P = .52). Exploratory studies showed no difference in disease control between 2 or 3 cycles of concurrent cisplatin; however, patients given 3 concurrent cycles had a significant increase in hearing impairment (40% vs 24%, P = .017). Only those who continued to receive 2 or more cycles of adjuvant cisplatin-fluorouracil achieved significant improvement in distant control (73% vs 65%, P = .037) and maximal survival gain. CONCLUSION: The addition of concurrent cisplatin plus adjuvant cisplatin-fluorouracil could significantly improve overall survival and disease control without incurring a significant increase in late toxicity or noncancer deaths. Exploratory analyses suggested that both the concurrent and the adjuvant phases contributed to tumor control. Furthermore, the number of concurrent cycles could be reduced from 3 to 2 cycles in order to achieve a similar survival benefit without incurring an excessive increase in hearing impairment. This is a useful hypothesis that warrants further validation.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ng WT, Tung SY, Lee V, et al. Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma-Exploration for Achieving Optimal 10-Year Therapeutic Ratio. Int J Radiat Oncol Biol Phys. 2018. PMID: 29885997. doi:10.1016/j.ijrobp.2018.04.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。